Methods for treating cone dystrophy with neuronal viability factor, RDCVF2
US9575075B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 5, 2008 |
| Grant date | Feb 21, 2017 |
| Priority date | — |
| Expiry date | Apr 19, 2032 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2835
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO:10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.